Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells

Biomedicine and Pharmacotherapy

Volumn 65, Issue 4, 2011, Pages 260-270

  Rama, Ana R ^a   Prados, Jose ^a   Melguizo, Consolacion ^a   Burgos, Miguel ^b   Alvarez, Pablo J ^a   Rodriguez Serrano, Fernando ^a   Ramos, Juan L ^c   Aranega, A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Department of Genetics   (Spain)

^c CSIC   (Spain)

Author keywords

Breast cancer; Combined therapy; Cytotoxic therapy; E gene; Gene therapy; Multicellular tumour spheroid

Indexed keywords

DOCETAXEL; DOXORUBICIN; MEMBRANE PROTEIN; PACLITAXEL; PLASMID VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; E GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; MONOTHERAPY; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHEROIDS, CELLULAR; TRANSFECTION; VIRAL PROTEINS;

EID: 79960433288     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.01.002     Document Type: Article

References (39)

1. Morris P.G., McArthur H.L., Hudis C.A. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009, 10:967-981.
2. Jassem J., Carroll C., Ward S.E., Simpson E., Hind D. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 2009, 45(16):2749-2758.
3. Guarneri V., Conte P., Metastatic breast cancer. therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009, 14(7):645-656.
4. Tang S.C. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Cancer Invest 2009, 27(2):206-214.
5. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007, 28(1):4-41.
6. Prados J., Melguizo C., Rama A., Ortiz R., Boulaiz H., Rodriguez-Serrano F., et al. Combined therapy using suicide gef gene and Paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells. Int J Oncol 2008, 33(1):121-127.
7. Shieh G.S., Shiau A.L., Yo Y.T., Lin P.R., Chang C.C., Tzai T.S., et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006, 66(20):9957-9966.
8. Deharvengt S., Rejiba S., Wack S., Aprahamian M., Hajri A. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 2007, 30(6):1397-1406.
9. Liang C.Y., Ma P., Liu X.L. RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells. Zhonghua Yi Xue Za Zhi 2008, 88(24):1703-1706.
10. Emi M., Kim R., Tanabe K., Uchida Y., Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005, 7(6):940-952.
11. Abaza M.S., Al-Saffar A., Al-Sawan S., Al-Attiyah R. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 2008, 29(5):287-303.
12. Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008, 7:60.
13. Showalter S.L., Huang Y.H., Witkiewicz A., Costantino C.L., Yeo C.J., Green J.J., et al. Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells. Cancer Biol Ther 2008, 7:1584-1590.
14. Zhao J.M., Wen Z.J., Li Q., Wang Y., Wu H., Xu J., et al. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 2008, 22:4272-4280.
15. Brandtner E.M., Kodajova P., Hlavaty J., Jandl G., Tabotta W., Salmons B., et al. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches. J Gene Med 2008, 10:113-122.
16. Boulaiz H., Prados J., Melguizo C., García A.M., Marchal J.A., Ramos J.L., et al. Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. Br J Cancer 2003, 89(1):192-198.
17. Boulaiz H., Prados J., Marchal J.A., García A.M., Alvarez L., Melguizo C., et al. Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle. Cancer Sci 2003, 94(6):564-568.
18. Prados J., Melguizo C., Rama A.R., Ortiz R., Segura A., Boulaiz H., et al. Gef gene therapy enhances the therapeutic efficacy of Doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2010, 66(1):69-78.
19. Bernhardt T.G., Roof W.D., Young R. Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis. Proc Natl Acad Sci USA 2000, 97(8):4297-4302.
20. Ortiz R., Prados J., Melguizo C., Rama A.R., Segura A., Rodríguez-Serrano F., et al. The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo. J Mol Med 2009, 87(9):899-911.
21. Witte A., Wanner G., Bläsi U., Halfmann G., Szostak M., Lubitz W. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J Bacteriol 1990, 172(7):4109-4114.
22. Monazzam A., Razifar P., Simonsson M., Qvarnström F., Josephsson R., Blomqvist C., et al. Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring. Cancer Cell Int 2006, 6:6.
23. Jones S.E., Metastatic breast cancer. the treatment challenge. Clin Breast Cancer 2008, 8(3):224-233.
24. He P., Zhu D., Hu J.J., Peng J., Chen L.S., Lu G.X. pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth. Mol Biol Rep 2010, 37(3):1597-1604.
25. Song W., Dong Z., Jin T., Mantellini M.G., Núñez G., Nör J.E. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther 2008, 15(10):667-675.
26. Akar U., Chaves-Reyez A., Barria M., Tari A., Sanguino A., Kondo Y., et al. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 2008, 4(5):669-679.
27. Kong H., Huang Z.H., Li Q., Yang L.C., Yu J.L., Li Z. Adenovirusmediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2006, 28(6):907-910.
28. Dachs G.U., Tupper J., Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005, 16(4):349-359.
29. Zielinski C.C. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Williston Park) 2003, 17(12):36-40.
30. Burdette-Radoux S., Wood M.E., Olin J.J., Laughlin R.S., Crocker A.M., Ashikaga T., et al. Phase I/II trial of adjuvant dose-dense Docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer. Breast J 2007, 13(3):274-280.
31. von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer. phase III randomized GeparTrio study. J Natl Cancer Inst 2008, 100(8):552-562.
32. Dong K., Wang R., Wang X., Lin F., Shen J.J., Gao P., et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009, 113(3):443-456.
33. Han T.K., Dao M.L. Enhancement of salivary IgA response to a DNA vaccine against Streptococcus mutans wall-associated protein A in mice by plasmid-based adjuvants. J Med Microbiol 2007, 56(5):675-680.
34. Gao X., Wu L., O'Neil R.G. Temperature-modulated diversity of TRPV4 channel gating. activation by physical stresses and phorbol ester derivatives through protein kinase C-dependent and -independent pathways. J Biol Chem 2003, 278(29):27129-27137.
35. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005, 103(8):1551-1560.
36. Jang J.Y., Choi Y., Jeon Y.K., Aung K.C., Kim C.W. Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo. BMC Cancer 2008, 8:160.
37. Maddika S., Mendoza F.J., Hauff K., Zamzow C.R., Paranjothy T., Los M. Cancer-selective therapy of the future. apoptin and its mechanism of action. Cancer Biol Ther 2006, 5(1):10-19.
38. Aroui S., Brahim S., De Waard M., Bréard J., Kenani A. Efficient induction of apoptosis by Doxorubicin coupled to cell-penetrating peptides compared to unconjugated Doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett 2009, 285(1):28-38.
39. Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A., Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004, 112(4):713-721.